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Hypothesis 
Hydrocortisone infusion in severe community-acquired 
pneumonia (CAP) attenuates systemic inflammation and 
leads to earlier resolution of pneumonia and a reduction in 
sepsis-related complications. 
Methods 
Design: Prospective, randomized, double-blind, placebo-
controlled multi-center clinical trial. 
Setting: Intensive care units and respiratory intermediate 
units of six hospitals in Italy between July 2000 and March 
2003. 
Subjects: Forty-six patients admitted to the intensive care 
unit with clinical and radiographic evidence of pneumonia 
and either two minor or one major 1993 American Thoracic 
Society criterion for severe pneumonia. Patients with 
nosocomial pneumonia, immunosuppression, acute burn 
injury, pregnancy, life expectancy less than 3 months, and 
conditions requiring more than 0.5 mg/kg/day of prednisone 
equivalent (such as acute asthma and COPD) were 
excluded. 
Intervention: Subjects were randomly assigned to receive 
hydrocortisone infusion or placebo in addition to protocol 
guided antimicrobial therapy. Hydrocortisone was given as 
an intravenous 200mg bolus followed by infusion at a rate of 
10 mg/hour for 7 days. 
Outcomes: The primary end-points of the study were 
improvement in PaO2:FiO2 (PaO2:FiO2 >300 or ≥100 
increase from study entry) and multiple organ dysfunction 
syndrome (MODS) score by Study Day 8, and development 
of delayed septic shock. The secondary end-points were 
duration of mechanical ventilation, length of ICU and 
hospital stay, and survival to hospital discharge and to 60 
days.  
Results 
The hydrocortisone group had lower PaO2:FiO2, higher 
chest radiograph score and C-reactive protein (CRP) level 
at study entry. However by study day 8, treated patients 
had, compared with control subjects, a significant 
improvement in PaO2:FiO2 (p=0.002) and chest radiograph 
score (p<0.0001), and a significant reduction in CRP levels 
(p=0.01), MODS score (p=0.003), and delayed septic shock 
(p=0.001). Hydrocortisone treatment was associated with a 
significant reduction in length of hospital stay (p=0.03) and 
mortality (p=0.009). There were seven deaths in the control 
group, whereas none in the hydrocortisone group. 
Conclusion 
A seven-day course of low-dose hydrocortisone infusion in 
patients with severe community-acquired pneumonia was 
associated with a significant reduction in duration of 
mechanical ventilation, hospital length of stay, and hospital 
mortality. 
Commentary 
The role of glucocorticoids in patients with severe CAP is 
uncertain. In patients with septic shock, however, several 
recent randomized controlled trials have shown that low 
doses of glucocorticoids administered for a prolonged 
period of time shorten the duration of shock and improve 
survival [2-4]. Although some of the patients in these studies Critical Care  December 2005  Vol 9 No 6    Raghavan and Kellum 
had CAP as a source of sepsis, patients with CAP were not 
analyzed separately. The study by Confalonieri and 
colleagues is the first randomized study to evaluate the 
efficacy and safety of low-dose hydrocortisone infusion 
specifically in patients with severe CAP. The investigators in 
this trial also attempted to explore the role of corticosteroids 
in attenuating inflammatory response as assessed by serum 
CRP levels. Previous studies assessing the role of 
glucocorticoids in patients with CAP found no benefit in 
terms of inflammatory mediator release but these studies 
either used shorter courses of glucocorticoids or were not 
powered to detect treatment differences [5-7]. 
The authors in the current study used a sequential trial 
design with interim analyses approximately every 20 
patients in order to reduce the number of patients exposed 
to “inferior” treatment through early study termination if 
treatment-related outcome differences emerged. In fact, the 
study was stopped early, after only 46 subjects were 
enrolled, when improvements in PaO2:FiO2 and hospital 
mortality were observed with hydrocortisone. There is little 
doubt that clinical trials should be stopped early when there 
is evidence of harm, but decisions to stop early for benefit 
must be made cautiously, especially when surrogate 
endpoints, such as improvement in PaO2:FiO2, are primary 
outcome variables. Though the mortality difference was 
highly significant (absolute risk reduction of 30% for hospital 
mortality, p=0.009, NNT=3.3), only one or two deaths in the 
hydrocortisone group would have been sufficient to tip the 
balance toward a non-significant mortality difference and in 
favor of study continuation, rather than early termination of 
the trial. 
This consideration notwithstanding, some important 
limitations of this study deserve consideration. Because the 
sample size was small, randomization did not achieve a 
balance of prognostic factors between groups. Baseline 
PaO2:FiO2 values, CRP levels, and chest radiograph scores 
were significantly worse in the hydrocortisone group and 
there was a trend towards more comorbid illness, greater 
age, and increased initial use of mechanical ventilation in 
the placebo arm. Although the differences that reached 
statistical significance would seem to bias against the 
treatment, these differences do raise concerns that the 
groups were not similar at the start of the trial. With the 
current knowledge of the possible beneficial effects of 
corticosteroids in patients with severe sepsis and adrenal 
insufficiency [2], one also might question whether the 
distribution of adrenal insufficiency was different between 
the placebo and hydrocortisone groups. Unfortunately, no 
data are provided regarding the adrenal function of these 
patients. In a study of glucocorticoids, it is almost impossible 
to keep the investigators completely blinded as white blood 
cell counts and plasma glucose levels are likely to be 
elevated in the glucocorticoid group, thereby introducing the 
potential biases associated with inadequate blinding of the 
investigators. As acknowledged by the authors, it is difficult 
in a small study to control for center-specific effects, 
especially when early study termination precludes any 
meaningful subgroup analyses. Of particular concern is that 
individual centers had very different outcomes (center 
specific mortality ranged from 0% to 36%) and that 
treatment allocation was not balanced at each site. A 
smaller randomization block size would have solved this 
latter issue, but only a larger study could have addressed 
center-specific effects. 
Recommendation 
This study suggests that hydrocortisone may improve 
survival in patients with severe CAP. However, as for any 
drug therapy, most experts argue for a second study to 
confirm the results. Given the small sample size and very 
low mortality rate in the treatment arm, a larger multi-center 
randomized controlled trial with 90-day mortality [8,9] as the 
primary end point is needed before hydrocortisone can be 
recommended as routine therapy for severe CAP. 
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